Search Results 931-940 of 17587 for Assay

1. A Study to Evaluate Regional Radiotherapy in Biomarker Low-Risk Node Positive Breast Cancer - Mayo Clinic

   ... assays described in the protocol may be conducted. Patient must consent to provision of samples of blood in order that the specific correlative marker ...

2. MK-8228 (Letermovir) PK In Pediatric Kidney Transplant Recipients - Mayo Clinic

   ... assay). Has suspected or known hypersensitivity to active or inactive ingredients of LET formulations. Has Child-Pugh B or C hepatic insufficiency within 14 ...

3. Encaleret Compared to Standard of Care in Participants with Autosomal Dominant Hypocalcemia Type 1 - Mayo Clinic

   Participants who are in complete remission from Hepatitis C as evidence by sensitive assay ≥ 12 weeks after completion of HCV therapy may participate in the ...

4. Ph 1b Study to Evaluate GSK2110183 in Combination with Bortezomib and Dexamethasone in Subjects with Multiple Myeloma - Mayo Clinic

   ... assay: Involved FLC level ≥5mg/dl (≥50mg/l) and an abnormal serum free light chain ratio (<0.26 or >1.65); Biopsy proven plasmacytoma (should be measured ...

5. Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair - Mayo Clinic

   ... assay are not eligible to participate unless they also have MMR testing by IHC and are found to have dMMR (i.e. loss of one or more MMR proteins); Patients ...

6. A Study to Compare Venetoclax with Fulvestrant vs. Fulvestrant Alone in Women with Locally Advanced or Metastatic HER2-negative Cancer who Have Progressed or Recurred on a CDK4/6 Inhibitor - Mayo Clinic

   Patients who have a positive HCV antibody test are eligible for the study if a PCR assay is negative for HCV RNA. History of other malignancies within the ...

7. Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma - Mayo Clinic

   ... assay: involved SFLCs >/= 10 mg/dL (>/= 100 mg/L) and an abnormal SFLC ratio (<0.26 or >1.65). Female participants of childbearing potential must have a ...

8. Testing Whether The Addition Of Carboplatin Chemotherapy To Cabazitaxel Chemotherapy Will Improve Outcomes Compared To Cabazitaxel Alone In People With Castrate-Resistant Prostate Cancer That Has Spread Beyond The Prostate To Other Parts Of The Body - Mayo Clinic

   ... assays for TP53, RB1 and PTEN. In addition, while not mandated, CLIA certified next generation sequencing (NGS) of tumor deoxyribonucleic acid (DNA) and/or ...

9. Diarrhea Clinical Trials - Mayo Clinic Research

   The investigators aim to study the ability of the HPLC assay for fecal bile acids to demonstrate responsiveness after treatment with Colesevelam. A Study of ...

10. Anatomic and Clinical Pathology Residency (Florida) - Curriculum

    ... assay (ELISA), multiplex flow immunoassay, latex agglutination, and lateral flow immunoassays. In addition to weekly didactics, residents also participate ...